Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Large-Cell Lymphoma
Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
November 22nd, 2007
Seattle Genetics, Inc. (Nasdaq: SGEN) announced positive data from an ongoing phase I trial of SGN-35, a proprietary antibody-drug conjugate (ADC) product candidate. Multiple objective responses have been observed at well-tolerated doses of SGN-35 in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive malignancies. The data were reported at the 7th International Symposium on Hodgkin Lymphoma in Cologne, Germany. More than 75 percent of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses. Twelve additional patients had stable disease and seven had progressive disease. Of...
Source: Genetics & Environmental Business Week (2007-11-22)
|
